A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

Summary

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Teclistamab

  Teclistamab will be administered as SC injection.

• Drug
  Daratumumab

  Daratumumab will be administered as SC injection.

• Drug
  Lenalidomide

  Lenalidomide will be administered orally.

• Drug
  Dexamethasone

  Dexamethasone will be administered either orally or intravenously (IV).

• Drug
  Talquetamab

  Talquetamab will be administered as SC injection.

Locations (265)